CN101043883A - (z)－2－氰基－3－羟基－丁－2－烯酸－(4'－三氟甲基苯基)－酰胺用于治疗炎症性肠病的用途 - Google Patents

(z)－2－氰基－3－羟基－丁－2－烯酸－(4'－三氟甲基苯基)－酰胺用于治疗炎症性肠病的用途 Download PDF

Info

Publication number
CN101043883A
CN101043883A CNA2005800357982A CN200580035798A CN101043883A CN 101043883 A CN101043883 A CN 101043883A CN A2005800357982 A CNA2005800357982 A CN A2005800357982A CN 200580035798 A CN200580035798 A CN 200580035798A CN 101043883 A CN101043883 A CN 101043883A
Authority
CN
China
Prior art keywords
acid
inflammatory bowel
disease
formula
bowel disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800357982A
Other languages
English (en)
Chinese (zh)
Inventor
R·D·沙耶尔
S·D·斯蒂伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of CN101043883A publication Critical patent/CN101043883A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNA2005800357982A 2004-10-19 2005-10-18 (z)－2－氰基－3－羟基－丁－2－烯酸－(4'－三氟甲基苯基)－酰胺用于治疗炎症性肠病的用途 Pending CN101043883A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62025504P 2004-10-19 2004-10-19
US60/620,255 2004-10-19

Publications (1)

Publication Number Publication Date
CN101043883A true CN101043883A (zh) 2007-09-26

Family

ID=35636963

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800357982A Pending CN101043883A (zh) 2004-10-19 2005-10-18 (z)－2－氰基－3－羟基－丁－2－烯酸－(4'－三氟甲基苯基)－酰胺用于治疗炎症性肠病的用途

Country Status (13)

Country Link
US (1) US20070197643A1 (enExample)
EP (1) EP1804782A1 (enExample)
JP (1) JP2008517059A (enExample)
KR (1) KR20070065888A (enExample)
CN (1) CN101043883A (enExample)
AU (1) AU2005295511A1 (enExample)
BR (1) BRPI0518205A (enExample)
CA (1) CA2584655A1 (enExample)
IL (1) IL182591A0 (enExample)
MX (1) MX2007004265A (enExample)
RU (1) RU2007118691A (enExample)
SG (1) SG142305A1 (enExample)
WO (1) WO2006044741A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102470116A (zh) * 2009-07-10 2012-05-23 赛诺菲-安万特美国有限责任公司 使用特立氟胺与干扰素β的组合治疗多发性硬化症
CN102596184A (zh) * 2009-09-18 2012-07-18 赛诺菲 稳定性提高的(z)-2-氰基-3-羟基-丁-2-烯酸-(4’-三氟甲基苯基)-酰胺片剂制剂

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615267A1 (en) 2005-07-11 2007-01-18 Ablation Frontiers, Inc. Low power tissue ablation system
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2100881A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Pyrimidyl- or pyridinylaminobenzoic acid derivatives
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
US20140031383A1 (en) 2011-02-08 2014-01-30 Dana-Farber Cancer Institute, Inc. Methods for treatment of melanoma
JOP20190207A1 (ar) * 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
ATE269295T1 (de) * 1998-04-17 2004-07-15 Parker Hughes Inst Btk inhibitoren und verfahren zur identifizierung und verwendung
GB0005345D0 (en) * 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
JP2004536786A (ja) * 2001-03-02 2004-12-09 メディミューン，インコーポレイテッド インテグリンαｖβ３拮抗薬を他の予防薬もしくは治療薬と組み合わせて投与することによる炎症性疾患または自己免疫疾患の予防または治療方法
ES2305287T3 (es) * 2001-04-05 2008-11-01 Aventis Pharmaceuticals Inc. Uso de (4'-trifluorometifenil)-amida del acido (z)-ciano-3-hidroxi-but-2-enoico para tratar la esclerosis multiple.
CA2498045A1 (en) * 2002-09-06 2004-03-25 Schebo Biotech Ag Compounds for modulating the glycolosis enzyme complex and/or transaminase complex

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102470116A (zh) * 2009-07-10 2012-05-23 赛诺菲-安万特美国有限责任公司 使用特立氟胺与干扰素β的组合治疗多发性硬化症
CN102596184A (zh) * 2009-09-18 2012-07-18 赛诺菲 稳定性提高的(z)-2-氰基-3-羟基-丁-2-烯酸-(4’-三氟甲基苯基)-酰胺片剂制剂
CN102596184B (zh) * 2009-09-18 2015-03-11 赛诺菲 稳定性提高的(z)-2-氰基-3-羟基-丁-2-烯酸-(4’-三氟甲基苯基)-酰胺片剂制剂
CN104666272A (zh) * 2009-09-18 2015-06-03 赛诺菲 稳定性提高的(z)-2-氰基-3-羟基-丁-2-烯酸-(4’-三氟甲基苯基)-酰胺片剂制剂

Also Published As

Publication number Publication date
RU2007118691A (ru) 2008-11-27
EP1804782A1 (en) 2007-07-11
WO2006044741A1 (en) 2006-04-27
JP2008517059A (ja) 2008-05-22
BRPI0518205A (pt) 2008-11-04
AU2005295511A1 (en) 2006-04-27
CA2584655A1 (en) 2006-04-27
MX2007004265A (es) 2008-03-04
KR20070065888A (ko) 2007-06-25
IL182591A0 (en) 2007-09-20
US20070197643A1 (en) 2007-08-23
SG142305A1 (en) 2008-05-28

Similar Documents

Publication Publication Date Title
US20070197643A1 (en) Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
JP2002537332A (ja) 内臓痛を予防及び治療するためのガバペンチン誘導体
JP4681116B2 (ja) 胃腸損傷を防止および治療するためのｇａｂａ類縁体
US9694027B2 (en) Pyrazole derivative and use thereof for medical purposes
CA2443285C (en) Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
KR102489052B1 (ko) 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
US6794410B2 (en) Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis
US20200375954A1 (en) Therapeutic agent for food competence disorder in stomach
HK1106701A (en) Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
EP1192944B1 (en) Use of pregabalin for treating asthma
US11458112B2 (en) Compositions and methods for inducing defecation
JP6100510B2 (ja) 抗感冒剤
CN1346268A (zh) 下部尿路症治疗用医药组合物
US9649289B1 (en) Method and composition for treating dysbiosis and related disease states
CN113015524A (zh) 氨基甲酸酯化合物和包含其的制剂在预防、缓解或治疗急性应激障碍或创伤后应激障碍中的用途
TWI848230B (zh) 口服之醫藥組成物之用途
CN1649590A (zh) 包含拉呋替丁的治疗剂
CN112641765B (zh) 丙泊酚的抗疲劳制药用途
US20240423933A1 (en) Drugs for treating neurodevelopmental disorders
JP4598674B2 (ja) 統合失調症治療剤
TW200533337A (en) Pharmaceutical compositions for prevention or treatment of diseases associated with esophageal dysmotility and use thereof
JP2021172639A (ja) 医薬組成物
JP2004224747A (ja) 腸疾患治療薬
CN101043890A (zh) △－9－the治疗多发性硬化

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1106701

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070926

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1106701

Country of ref document: HK